Page 95 - 79_03

Estabilidad
microbiológica
de
medicamentos…

10.
Hessel
H,
et
al.
The
genotoxic
risk
of
hospital,
pharmacy
and
medical
personnel

occupationally
exposed
to
cytostatic
drugs-­--­-evaluation
by
the
micronucleus
assay.
Mutat

Res.
2001;497(1-­-2):101-­-9.

11.
Roth
S,
et
al.
Analysis
of
chromosomal
aberrations,
sister-­-chromatid
exchanges
and

micronuclei
in
peripheral
lymphocytes
of
pharmacists
before
and
after
working
with

cytostatic
drugs.
Mutat
Res.
1994;325(4):157-­-62.

12.
McDiarmid
MA,
et
al.
Chromosome
5
and
7
abnormalities
in
oncology
personnel
handling

anticancer
drugs.
J
Occup
Environ
Med.
2010;52(10):1028-­-34.

13.
Dranitsaris
G,
et
al.
Are
health
care
providers
who
work
with
cancer
drugs
at
an
increased

risk
for
toxic
events?
A
systematic
review
and
meta-­-analysis
of
the
literature.
J
Oncol

Pharm
Pract.
2005;11(2):69-­-78.

14. Sauere-­-Cubizolles
MJ,
et
al.
Ectopic
pregnancy
and
occupational
exposure
to
antineoplastic

drugs.
Lancet.
1993;
341:
1169-­-71.

15. Hansen
J,
et
al.
Cancer
morbidity
among
Danish
female
pharmacy
technicians.
Scand
J

Work
Environ
Health.
1994;20(1):22-­-6.

16. Valanis
BG,
et
al.
Association
of
antineoplastic
drug
handling
with
acute
adverse
effects
in

pharmacy
personnel.
Am
J
Hosp
Pharm.
1993;50(3):455-­-62.

17. Chaffee
BW,
et
al.
Guidelines
for
the
safe
handling
of
hazardous
drugs:
consensus

recommendations.
Am
J
Health
Syst
Pharm.
2010;67(18):1545-­-6.

18.
International
Society
of
Oncology
Pharmacy
Practicioners
Standards
Committee.
ISOPP

standards
of
practice.
Safe
handling
of
cytotoxics.
J
Oncol
Pharm
Pract.
2007;13
Suppl:1-­-
81.

19. National
Institute
for
Occupational
Safety
and
Health.
Preventing
occupational
exposure
to

antineoplastic
and
other
hazardous
drugs
in
health
care
settings.
NIOSH
publication
nº

2004-­-165.
www.cdc.gov/niosh/docs/2004-­-165
(acceso
diciembre
2011).

20. Sessink
P,
et
al.
Evaluation
of
the
PhaSeal
hazardous
drug
containment
system.
Hosp

Pharm.
1999;
34:
1311-­-7.

21. Connor
T,
et
al.
Effectiveness
of
a
closed-­-system
device
in
containing
surface

contamination
with
cyclophosphamide
and
ifosfamide
in
an
I.V.
admixture
area.
Am
J

Health
Syst
Pharm.
2002;
59:
68-­-72.

22. Harrison
B,
et
al.
Comparison
of
surface
contamination
with
cyclophosphamide
and

fluorouracil
using
a
closed-­-system
drug
transfer
device
versus
standard
preparation

techniques.
Am
J
Health
Syst
Pharm.
2006;
63:
1736-­-44.

23. Siderov
J,
et
al.
Reducing
workplace
cytotoxic
surface
contamination
using
a
closed-­-system

drug
transfer
device.
J
Oncol
Pharm
Pract.
2010;16(1):19-­-25.

24. Yoshida
J,
et
al.
Use
of
a
closed
system
device
to
reduce
occupational
contamination
and

exposure
to
antineoplastic
drugs
in
the
hospital
work
environment.
Ann
Occup
Hyg.

2009;53(2):153-­-60.

25. Vandenbroucke
J,
et
al.
How
to
protect
environment
and
employees
against
cytotoxic

agents,
the
UZ
Ghent
experience.
J
Oncol
Pharm
Pract.
2001;
6:
146-­-152.

26. United
States
Pharmacopeia,
Inc.
U.S.
Pharmacopeia
27.
Chapter
<797>:
Pharmaceutical

Compounding
-­-
Sterile
Preparations.
Rockville,
MD:
United
States
Pharmacopeial

Convention,
2004;2461-­-77.

27. Wilson
JP,
et
al.
Aseptic
technique
as
a
safety
precaution
in
the
preparation
of

antineoplastic
agents.
Hosp
Pharm.
1981;16(11):575-­-6,
579-­-81.

28. De
Prijck
K,
et
al.
Microbiological
challenge
of
four
protective
devices
for
the

reconstitution
of
cytotoxic
agents.
Lett
Appl
Microbiol.
2008;47(6):543-­-8.

29. McMichael
D,
et
al.
Utility
of
the
PhaSeal
closed
system
drug
transfer
device.
The
American

Journal
of
Pharmacy
Benefits.
2011;3(1):
9-­-16.

479